Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim clinical programs — 94 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Boehringer Ingelheim projects

94 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.

Boehringer Ingelheim has 94 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

94 programs

Clinical programs

Page 1 of 2

  1. 0352-2189

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  2. 0352-2190

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  3. 1230.15

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  4. 1245-0358

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  5. 1305-0037

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  6. 1305-0039

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  7. 1305-0051

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  8. 1305-0113

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  9. 1305-0119

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  10. 1366-0042

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  11. 1368-0151

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  12. 1378-0024

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  13. 1378-0025

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  14. 1378-0043

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  15. 1397-0021

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  16. 1397-0022

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. 1397-0029

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. 1403-0001

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  19. 1403-0002

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  20. 1403-0004

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  21. 1404-0008

    Boehringer Ingelheim

    Overweight, Obesity

    phase 1 other active

    1 trial

  22. 1404-0009

    Boehringer Ingelheim

    Renal impairment (mild, moderate and severe), Healthy

    phase 1 other active

    1 trial

  23. 1404-0011

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  24. 1404-0015

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  25. 1404-0074

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  26. 1404-0099

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  27. 1404-0103

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  28. 1404-0118

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  29. 14040047

    Boehringer Ingelheim

    No targeted indication. Male and female subjects with obesity.

    phase 1 other active

    1 trial

  30. 1434-0005

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  31. 1434-0006

    Boehringer Ingelheim

    healthy volunteer trial

    phase 1 other active

    1 trial

  32. 1434-0021

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  33. 1438-0001

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  34. 1438-0003

    Boehringer Ingelheim

    Glioma expressing DLL3

    phase 1 other active

    1 trial

  35. 1438-0007

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  36. 1438-0008

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  37. 1438-0009

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  38. 1443-0002

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  39. 1443-0003

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  40. 1447-0007

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  41. 1454-0015

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  42. 1456-0001

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  43. 1458-0006

    Boehringer Ingelheim

    Obesity

    phase 1 other active

    1 trial

  44. 1463-0001

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  45. 1472-0001

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  46. 1474-0002

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  47. 1479-0001

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  48. 1479-0014

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Boehringer Ingelheim have?

94 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.